Detalhe da pesquisa
1.
Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
Mult Scler
; 29(11-12): 1452-1464, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37691530
2.
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Mult Scler
; 28(10): 1591-1605, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35380078
3.
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
Neurol Ther
; 12(5): 1491-1515, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37450172
4.
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
N Engl J Med
; 355(11): 1124-40, 2006 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-16971719
5.
Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials.
Mult Scler J Exp Transl Clin
; 4(2): 2055217318778610, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29854416
6.
Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.
Paediatr Drugs
; 5(12): 833-41, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-14658924
7.
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
Neurology
; 82(8): 674-80, 2014 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-24463630